{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alum+%28Aluminum+Hydroxide+Suspension%29", "query": { "intervention": "Alum (Aluminum Hydroxide Suspension)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T02:15:06.461Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04985760", "title": "Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Madhu Chhanda Choudhary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2021-09-30", "completion_date": "2026-01-16", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 2, "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985760" }, { "nct_id": "NCT06680479", "title": "Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "CH505 TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-052-AF", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Suspension", "type": "BIOLOGICAL" }, { "name": "Sodium Chloride for Injection", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-04-01", "completion_date": "2028-04-14", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 24, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06680479" }, { "nct_id": "NCT03783130", "title": "Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Immunodeficiency Virus Prevention", "Human Immunodeficiency Virus (HIV)" ], "interventions": [ { "name": "VRC-HIVRGP096-00-VP", "type": "BIOLOGICAL" }, { "name": "Alum Adjuvant", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 16, "start_date": "2019-03-07", "completion_date": "2020-06-24", "has_results": true, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03783130" }, { "nct_id": "NCT04177355", "title": "Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "BG505 SOSIP.664 gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "3M-052-AF", "type": "BIOLOGICAL" }, { "name": "CpG 1018", "type": "BIOLOGICAL" }, { "name": "GLA-LSQ", "type": "BIOLOGICAL" }, { "name": "Alum (Aluminum Hydroxide Suspension)", "type": "BIOLOGICAL" }, { "name": "Trimer 4571", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 127, "start_date": "2020-01-13", "completion_date": "2024-11-04", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04177355" }, { "nct_id": "NCT04915768", "title": "Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CH505 TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-05-AF", "type": "BIOLOGICAL" }, { "name": "Aluminum hydroxide suspension", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 51, "start_date": "2023-01-23", "completion_date": "2025-07-15", "has_results": true, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 3, "location_summary": "Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04915768" }, { "nct_id": "NCT06796686", "title": "Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "426c.Mod.Core-C4b", "type": "BIOLOGICAL" }, { "name": "HxB2.WT.Core-C4b", "type": "BIOLOGICAL" }, { "name": "3M-052-AF adjuvant", "type": "BIOLOGICAL" }, { "name": "Aluminum hydroxide suspension (Alum) adjuvant", "type": "OTHER" }, { "name": "Diluent", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2025-03-17", "completion_date": "2027-01-15", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 6, "location_summary": "San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06796686" }, { "nct_id": "NCT06267872", "title": "A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "CD4BS CH505M5 Pr-NP1", "type": "BIOLOGICAL" }, { "name": "CH505TF chTrimer", "type": "BIOLOGICAL" }, { "name": "3M-052-AF (labeled as AP 60-702)", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Suspension (Alum)", "type": "BIOLOGICAL" }, { "name": "ACU-026-001-1 (labeled as empty LNP)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2024-10-07", "completion_date": "2026-09-12", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06267872" }, { "nct_id": "NCT02963909", "title": "A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Zika Virus Infection" ], "interventions": [ { "name": "IXIARO", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "YF Vax 17D Strain", "type": "BIOLOGICAL" }, { "name": "Zika Virus Purified Inactivated Vaccine (ZPIV)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 75, "start_date": "2016-11-01", "completion_date": "2018-10-30", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02963909" }, { "nct_id": "NCT03049488", "title": "Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus" ], "interventions": [ { "name": "VRC-RSVRGP084-00-VP", "type": "BIOLOGICAL" }, { "name": "Aluminum Hydroxide Suspension", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 95, "start_date": "2017-02-22", "completion_date": "2019-10-03", "has_results": true, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049488" }, { "nct_id": "NCT03879603", "title": "VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Venezuelan Equine Encephalitis", "Western Equine Encephalitis", "Eastern Equine Encephalitis", "Alphavirus Infections" ], "interventions": [ { "name": "VRC-WEVVLP073-00-VP", "type": "BIOLOGICAL" }, { "name": "VRC-GENMIX083-AL-VP", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 30, "start_date": "2019-04-02", "completion_date": "2020-02-26", "has_results": true, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-10-05T02:15:06.461Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03879603" } ] }